Aisling Capital related stories
All articles and analysis
Menlo Therapeutics attracts $50 mln Series CMenlo Park, California-based Menlo Therapeutics Inc, a pharmaceutical company focused on treating chronic pruritus and chronic cough, has raised $50 million in Series C funding. VenBio led the round with participation from other investors that included Novo Holdings A/S, Rock Springs Capital, Aisling Capital, Bay City Capital, Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital. In addition to the funding, Dr. Aaron Royston of VenBio will join Menlo Therapeutics' board of directors.
- Hearing aid maker Earlens Corp pulls in $118 mln
Earlens Corporation Inc, a hearing aid maker, has raised $118 million in a funding tally. Included in that figure is $73 million in Series C preferred stock financing and a debt facility with CRG LP for up to $45 million. Vertex Healthcare led the Series C round with participation from other investors that included Windham Venture Partners, Sightline Partners, New Enterprise Associates, Aisling Capital, Lightstone Ventures and Medtronic.
- KKR and Aisling Capital launches Ajax Health
KKR and Aisling Capital have formed a new platform Ajax Health, which will source and provide operational and financial supporting emerging medical device companies. No financial terms were disclosed. Duke Rohlen will lead Ajax.
- Verona Pharma debuts IPO
London-based Verona Pharma, a biopharmaceutical company, has priced its IPO of over 5.8 million shares at $13.50 per share. The stock began trading April 27, 2017 on the NASDAQ under the ticker symbol “VRNA.” Jefferies and Stifel are serving as the lead underwriters. Verona Pharma’s backers include Vivo Capital, OrbiMed, New Enterprise Associates, Abingworth, Henderson Global Investors and Aisling Capital.
- VC-backed Verona Pharma files for IPO
London-based Verona Pharma, a biopharmaceutical company, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. Verona plans on listing the stock on the NASDAQ under the ticker symbol "VRNA." Jefferies and Stifel are serving as the lead underwriters. Verona Pharma's backers include Vivo Capital, OrbiMed, New Enterprise Associates, Abingworth, Henderson Global Investors and Aisling Capital.
- Promentis Pharmaceuticals pulls in $26 mln Series C
Promentis Pharmaceuticals, a biopharmaceutical company focused on treating central nervous disorders, has raised $26 million in Series C funding. OrbiMed, F-Prime Capital Partners and Aisling Capital led the round with participation from other investors that included Black Pearl GmbH and the Golden Angel Network.
- Biohaven closes second tranche of $80 mln private placement
Biohaven Pharmaceutical Holding Company Ltd, a clinical stage biopharmaceutical company targeting neurological diseases, including rare disorders, has closed the second tranche of its $80 million private placement. Venrock was the lead investor. Other participants in the financing included Vivo Capital, RA Capital Management, Aisling Capital, Rock Springs Capital, John W. Childs, Greg Bailey, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations and Litmore Capital.
- Longitude Capital promotes Richardson to MD
Longitude Capital has promoted Dr. Josh Richardson to managing director. Richardson originally was hired by the company in 2011. Then from 2014 to early 2016, Richardson worked at HealthCor Management where he served as a public equities analyst. In 2016, Richardson rejoined Longitude Capital.